filmov
tv
Niraparib significantly improves outcomes for ovarian cancer patients
Показать описание
Dr Mirza speaks to ecancer at ESMO 2016 about results from the NOVA trial of niraparib, a PARP inhibitor, to treat platinum sensitive recurrent ovarian cancer.
Dr Mirza describes the significant extension of progression free survival in all patient subgroups assessed through the trial, hailing it as a 'break through'.
Dr Mirza describes the significant extension of progression free survival in all patient subgroups assessed through the trial, hailing it as a 'break through'.
0:03:23
0:01:18
0:09:25
0:50:32
0:01:30
0:03:26
0:06:02
0:03:10
0:01:13
0:02:25
0:01:50
0:05:13
0:00:43
0:01:14
0:01:48
0:06:25
0:02:35
0:02:39
0:03:08
0:01:54
0:19:09
0:10:25
0:06:57
0:12:51